Education
About Us
Working with TipRanks
Follow Us
Azitra Inc (AZTR)
:AZTR
AZTR Stock Chart & Stats
$0.30
-$0.02(-5.17%)
At close: 4:00 PM EST
$0.30
-$0.02(-5.17%)
Day’s Range― - ―
52-Week Range$0.26 - $3.91
Previous CloseN/A
Volume201.32K
Average Volume (3M)169.78K
Market Cap
$3.52M
Enterprise Value$3.79M
Total Cash (Recent Filing)$1.40M
Total Debt (Recent Filing)$795.25K
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Mar 13, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding10,740,697
10 Day Avg. Volume152,326
30 Day Avg. Volume169,784
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.28
Price to Sales (P/S)0.21
P/FCF Ratio-0.16
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.19
Enterprise Value/Ebitda-0.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial MilestonePositive top-line readout from the Phase 1b Netherton Syndrome trial in 1Q26 would validate the program and enable progression to mid-stage development.
Early Safety DataPositive initial safety data for ATR-12 supports tolerability and reduces early clinical development risk for the EGFR inhibitor rash program.
Liquidity SupportA committed $20M credit line offers additional liquidity that could extend operational runway and support near-term program advancement.
Bears Say
Dilution RiskAnalyst lowered the price target citing dilution concerns, indicating potential for future equity issuance that could dilute existing shareholders.
Financing Cost ImpactReduced analyst valuation could increase the cost of raising fresh capital and make securing favorable financing terms more difficult.
Valuation PressureThe analyst's price target reduction narrows perceived upside and may weaken buying interest among investors.
Azitra Inc News
AZTR FAQ
What was Azitra Inc’s price range in the past 12 months?
Azitra Inc lowest stock price was $0.26 and its highest was $3.91 in the past 12 months.
What is Azitra Inc’s market cap?
Azitra Inc’s market cap is $3.52M.
When is Azitra Inc’s upcoming earnings report date?
Azitra Inc’s upcoming earnings report date is Mar 13, 2026 which is in 53 days.
How were Azitra Inc’s earnings last quarter?
Azitra Inc released its earnings results on Nov 12, 2025. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$0.76 by $0.09.
Is Azitra Inc overvalued?
According to Wall Street analysts Azitra Inc’s price is currently Overvalued.
Does Azitra Inc pay dividends?
Azitra Inc does not currently pay dividends.
What is Azitra Inc’s EPS estimate?
Azitra Inc’s EPS estimate is -0.33.
How many shares outstanding does Azitra Inc have?
Azitra Inc has 10,740,697 shares outstanding.
What happened to Azitra Inc’s price movement after its last earnings report?
Azitra Inc reported an EPS of -$0.67 in its last earnings report, beating expectations of -$0.76. Following the earnings report the stock price went down -14.815%.
Which hedge fund is a major shareholder of Azitra Inc?
Currently, no hedge funds are holding shares in AZTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Azitra Inc
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
AZTR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
―
Insiders
0.15% Mutual Funds
― Other Institutional Investors
99.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---